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Background: The SafeBoosC phase II multicentre random-
ized clinical trial investigated the benefits and harms of moni-
toring cerebral oxygenation by near-infrared spectroscopy 
(NIRS) combined with an evidence-based treatment guideline 
vs. no NIRS data and treatment as usual in the control group 
during the first 72 h of life. The trial demonstrated a significant 
reduction in the burden of cerebral hypoxia in the experimen-
tal group. We now report the blindly assessed and analyzed 
treatment effects on electroencephalographic (EEG) outcomes 
(burst rate and spectral edge frequency 95% (SEF95)) and blood 
biomarkers of brain injury (S100β, brain fatty acid-binding pro-
tein, and neuroketal).
Methods: One hundred and sixty-six extremely preterm 
infants were randomized to either experimental or control 
group. EEG was recorded at 64 h of age and blood samples 
were collected at 6 and 64 h of age.
results: One hundred and thirty-three EEGs were evaluated. 
The two groups did not differ regarding burst rates (experi-
mental 7.2 vs. control 7.7 burst/min) or SEF95 (experimental 
18.1 vs. control 18.0 Hz). The two groups did not differ regard-
ing blood S100β, brain fatty acid-binding protein, and neuro-
ketal concentrations at 6 and 64 h (n = 123 participants).
conclusion: Treatment guided by NIRS reduced the cere-
bral burden of hypoxia without affecting EEG or the selected 
blood biomarkers.
the mortality in extremely preterm infants is approximately 25% and the prevalence of moderate and severe neurode-
velopmental impairment in the surviving infants is as high as 
25% (1). The etiology behind this neurodevelopmental impair-
ment is multifactorial and partly related to the immaturity of 
the respiratory and circulatory systems leading to episodes of 
cerebral hypoxia. Cerebral hypoxia, in turn, through complex 
interactions between destructive and developmental distur-
bances may lead to micro- and macroscopic structural brain 
damage (2). The outcome of relevance to the individual child 
is neurodevelopmental impairment and possible ensuing dis-
abilities, which cannot be determined before the child is fully 
grown. Therefore, there is a need for identifying early surro-
gate outcomes. Long before the age of reliable testing of neuro-
logical functions or intelligence, it is possible to visualize brain 
injuries such as intraventricular and parenchymal hemorrhage 
by early cranial ultrasound (3). Later cranial ultrasound may 
show ventricular dilatation as a sign of exvacuo dilatation 
caused by cerebral atrophy, or periventricular leukomalacia 
(2,4,5), whereas magnetic resonance imaging at term equiva-
lent age may show minor degrees of white matter damage (3). 
Even before structural brain damage is visible, there are other 
means of detecting injury to the brain of the extremely pre-
term infant. Several cohort studies have demonstrated good 
correlations between early electroencephalography (EEG) and 
later developmental outcomes (6,7). A number of biomarkers 
show correlation with brain injury. Blood S100β is elevated 
in newborn infants with intraventricular hemorrhage (8) and 
hypoxic–ischemic encephalopathy (9). Blood brain fatty acid-
binding protein (BFABP) is elevated in elderly patients with 
neurodegenerative diseases (10) and cerebrospinal fluid neu-
roketal is elevated in preterm infants with white matter dam-
age on magnetic resonance imaging (11).
The SafeBoosC phase II randomized trial demonstrated 
that the combination of cerebral oxygenation monitoring by 
near-infrared spectroscopy (NIRS) combined with an evi-
dence-based treatment guideline (12) vs. blinded collection of 
cerebral NIRS data and treatment as usual for 72 h significantly 
reduced the burden of cerebral hypoxia (13). To investigate the 
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possible benefits of the experimental intervention on putative 
surrogate outcomes (14–16), we recorded EEG with amplitude-
integrated EEG tracing at the end of the intervention. We also 
analyzed the blood taken at the beginning and at the end of the 
intervention for the brain injury molecular biomarkers S100β, 
BFABP, and neuroketal. We hypothesized that the intervention 
would reduce the interburst interval (IBI) (6), which was a sec-
ondary outcome in the trial. Furthermore, an increased EEG 
spectral edge frequency 95% (SEF95) (17) and decreased levels 
of the brain injury molecular biomarkers S100β, BFABP, and 
neuroketal (exploratory outcomes) were expected.
RESULTS
Infant Characteristics
Patient characteristics at entry were similar across intervention 
groups but the burden of cerebral hypoxia was significantly 
lower at the end of intervention (72 h of age) in the experi-
mental group vs. the control group (Table 1). There were no 
differences in GA and birth weight for infants with and with-
out EEG or with or without molecular biomarkers at the two 
time points, although more infants without EEG had an Apgar 
score below five points at 5 min.
Electroencephalography
Eight infants died before 64 h of age (three in the experimental 
group and five in the control group) and another eight infants 
did not have any EEG recordings. Thus, one hundred and fifty 
EEGs were recorded. Seventeen of the recorded EEGs were 
not evaluable, which include impossible to read (n = 7), too 
short (n = 2), no artifact-free epochs (n = 7), or the infant was 
too old at the time of the EEG recording (n = 1). In total, we 
therefore analyzed EEGs from 133 infants. Data were collected 
using eight different EEG monitors: Micromed EEG system 
(Mogliano, Veneta, Italy) (n = 29); Nervus monitor (Cephalon, 
Norresundby, Denmark) (n = 29); Olympic cerebral function 
monitor (Natus, Pleasanton, CA) (n = 29); BRM2 and BRM3 
(Natus, former Brainz monitor) (n = 16 and n = 3); NicoletOne 
video-EEG system (Carefusion, Madison, WI) (n  =  16); 
g.recorder (g-tec, Graz, Austria) (n  =  7); and Moberg CNS 
monitor (Moberg Research, Ambler, PA) (n = 4). The median 
age at the time of EEG recording, number of sedated infants, 
and the number of infants treated with opioid did not differ 
between the intervention groups (Table 2). The interobserver 
table 1. Entry variables and 72-h outcomes of the included infants
Infants with EEG Infants with blood samples at 6 and 64 h
Experimental 
group (n = 68)
Control group  
(n = 65)
Experimental 
group (n = 66)
Control group  
(n = 58)
At entry variables
  Birth weight (g), median (range) 821 (410–1,286) 880 (490–1,330) 772 (410–1,286) 880 (515–1,330)
  GA (wk), median (IQR) 26.6 (25.8–27.4) 27.0 (25.7–27.6) 26.6 (24.4–27.3) 27.0 (25.7–27.6)
  Infants below 26 wk of gestation, n (%) 20 (29) 20 (31) 23 (35) 18 (31)
  Twins, n (%) 15 (22) 13 (20) 14 (21) 10 (17)
  Apgar below 5 at 5 min, n (%) 10 (15) 9 (14) 12 (18) 8 (14)
  Antenatal steroids (complete course) 44 (65) 48 (74) 47 (71) 41 (71)
Outcomes at 72 h
  Burden of hyperoxia (%hours), median (IQR) 1.2 (0.4–11.8) 4 (0.2–29.5) 1.0 (0.3–6.2) 1.8 (0.2–21.3)
  Burden of hypoxia (%hours), median (IQR)* 16.6 (5.2–65.4) 52.9 (17.2–152.9) 16.6 (6.1–63.5) 63.0 (21.2–174.8)
IQR, inter quartile range; EEG, electroencephalography.
* P < 0.001 between experimental and control groups (13).
table 2. EEG recording details and results
EEG recording details
Experimental 
group (n = 68)
Control group 
(n = 65) P value
Age at EEG (h), median (IQR) 64.8 (62.7–68.5) 65.8 (62.4–68.4) NS
Epochs per infant, median (IQR) 12 (11–16) 12 (11–20) NS
Sampling frequency 256 Hz, 
n (%)
54 (79) 50 (77) NSa
Sampling frequency 200 Hz, 
n (%)
14 (21) 15 (23)
Data filtered at 2–15 Hz, n (%) 13 (20) 10 (16) NS
Opioid, n (%) 16 (24) 21 (32) NS
Sedative, n (%) 9 (13) 5 (8) NS
EEG results
  Severe burst suppression 3 (4) 2 (3)
  Burst suppression 11 (16) 7 (11)  0.75b
  Discontinuous 41 (60) 41 (63)
  Continuous 13 (20) 15 (23)
   Burst rate (bursts/min) 
mean (SE)c
7.2 (0.72) 7.7 (0.73) 0.51
   Spectral edge frequency 
95% (Hz), mean (SE)c
18.1 (0.10) 18.0 (0.10) 0.51
IQR, inter quartile range; SE, standard error; NS, nonsignificant; EEG, 
electroencephalography.
aChi-squared test of distribution of the sampling frequency between experimental 
and control. bChi-squared test of distribution of the rEEG classification between 
experimental and control. cResult of mixed modelling after random exclusion of one 
twin from each twin pair.
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agreement for the artifact rejection was 92% and the Kappa 
value was 0.61.
After inverse transformation, the IBIs were normally distrib-
uted and by multiplication by 60 s/min expressed as burst rate 
(bursts/min). Inter cluster correlations (ICCs) were above 0.15 
for both burst rate and SEF95. Therefore, the between-groups 
analyses were conducted after randomly excluding one of each 
twin pair. Univariate analysis for burst rate and SEF95 was 
unaffected by GA (P = 0.42 and P = 0.40). The burst rate was 
significantly affected by EEG filter (P < 0.0001), type of EEG 
device (P = 0.045), and opioid treatment (P = 0.004). SEF95 
was significantly affected by EEG sampling rate (P < 0.0001) 
and type of EEG device (P<0.0001). Type of EEG device and 
EEG filter and type of EEG device and EEG sampling rate were 
strongly correlated; therefore, only EEG filter and EEG sam-
pling rate, opioid treatment, and GA were retained in the mul-
tiple regression models. In multiple regression, the mean (SE) 
burst rate did not differ between the two intervention groups: 
experimental 7.2  bursts/min (0.72) vs. control 7.7  bursts/
min (0.73). The mean SEF95 (SE) did not differ between the 
intervention groups: experimental 18.1 Hz (0.10) vs. control 
18.0 Hz (0.10) (Table 2). The delta-, theta-, alpha-, and beta-
power bands did not differ between the intervention groups. 
The raw burst rates and SEF95 separated by EEG filter and 
EEG sampling rate are illustrated in Figure 1a,b. The unad-
justed burst rate (SD) was reduced in infants with intraven-
tricular hemorrhage grade III or periventricular hemorrhagic 
infraction on day 1–4 (n = 10): 5.6 bursts/min (3.6) compared 
to 9.8 bursts/min (5.0) in the remaining infants (n = 120).
Blood Biomarkers
One hundred and twenty-three infants (66 in the experimental 
group vs. 57 in the control group) had blood samples taken at 
both the time points (6 and 64 h of age). The concentrations of 
the three biomarkers in the blood did not differ between the 
intervention groups neither at 6 nor at 64 h of age (Table 3). 
The main effect of the intervention is illustrated in Figure 2.
The ICC between the twins was above 0.15 for all blood 
biomarkers. Therefore, all analyses were conducted after the 
exclusion of one random twin from each twin pair. The mixed-
model analysis or nonparametric analysis, in case of non-
normal distribution of the data, confirmed the findings above 
(Table 3). The blood biomarkers were similar in infants with 
and without intraventricular hemorrhage degree III or peri-
ventricular hemorrhagic infractions.
DISCUSSION
The reduction in the burden of cerebral hypoxia in the group 
receiving cerebral NIRS monitoring combined with an evi-
dence-based treatment guideline was not reflected in any of 
the early biomarkers of brain injury that were assessed in the 
SafeBoosC II trial.
The Randomized Clinical Trial Design
The SafeBoosC phase II trial was a randomized clinical multi-
centre trial. We blindly evaluated and analyzed EEGs in 84% 
(133/158) and blood samples in 78% (123/158) of the infants 
alive at the time of the scheduled EEG recording and blood 
sampling. To avoid biased regression coefficients (18), we ran-
domly excluded one of each twin pair, if the ICC was above 
0.15.
The Challenges of EEG Recording
The EEGs were recorded with eight different devices. We 
therefore used a multiple regression model with corrections 
for EEG sampling specifications (EEG filter and EEG sampling 
rate). The difference in SEF95 given the different sampling rates 
of the EEG devices was not surprising since this was linked 
to the differences in frequency resolution of the Fast Fourier 
Transform given the different sampling rates. Some of the EEG 
Figure 1. Intervention effects on EEG outcomes. (a) Intervention effect on burst rates, according to EEG filter of the device. (b) Intervention effect on 
spectral edge frequency 95%, according to the EEG sampling rate of the device. □ = control group, ■ = experimental group.
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amplifiers used were equipped with a band pass filter from 2 
to 15 Hz. This clearly affected the detection of burst rates since 
the algorithm used for this was based on co-occurrence of 
slow- and high-frequency oscillations (19). Nevertheless, the 
burst rates in the SafeBoosC II trial were in line with previ-
ously published results in this group of infants (6,20,21) and 
the IBIs were longer in preterm infants with intraventricular 
hemorrhage grade III or periventricular hemorrhagic infrac-
tions, which has also previously been observed (22). However, 
we did not find a correlation between IBI and GA above or 
below 26 wk; this could be explained by the limited range of 
GA in the SafeBoosC trial. We therefore believe that the EEG 
data are robust and the results are reliable. While it is feasible 
to use EEG as an outcome in a multicentre randomized clini-
cal trial, it should be realized that working with different EEG 
devices may complicate the analyses by adding heterogeneity.
The Relevance of the Chosen Biomarkers
EEG. In term newborn infants, severe hypoxic–ischemic brain 
injury is associated with EEG burst suppression, lasting hours 
to days and predicting later neurodevelopmental outcome and 
death (23,24). EEG burst rate is reduced in preterm infants 
when arterial PCO2  and blood glucose concentrations are out-
side the normal range (20). Furthermore in preterm infants, 
permissive hypercapnia has been associated with increased 
power in the delta band of the EEG (25). Therefore, we 
hypothesized that EEG would be a sensitive surrogate marker 
of any clinically relevant brain effect of the reduction in cere-
bral hypoxia or hyperoxia that was aimed for in the SafeBoosC 
II trial. While the effect on cerebral hyperoxia was small and 
statistically insignificant, the reduction of cerebral hypoxia 
was highly statistically significant between the intervention 
groups, as well as potentially clinically relevant—amounting 
to more than a 50% reduction in cerebral hypoxia (13). We 
therefore expected the EEG to be different in the interven-
tion groups. Furthermore, our present analyses are not able 
to determine if IBI or SEF95 is able to predict the long-term 
cerebral outcome of preterm infants. Several studies have 
investigated the predictive value of different EEG variables 
and later neurodevelopmental outcome, although the vari-
ables and the timing of the EEG recording that have been used 
differ (6,7,22), and therefore EEG should not yet be discarded 
table 3. Molecular brain injury biomarkers
Biomarker (time) n Median (pg/ml) IQR (pg/ml)
P value
Unadjusted  
analysis
Adjusted analysis with 
exclusion of one random 
twin from each twin pair
S100Beta (6 h) E = 75 696 341–983
0.26
0.50a
C = 68 795 408–1,130
S100Beta (64 h) E = 70 602 267–1,024
0.51
C = 63 601 330–1,074
BFABP (6 h) E = 72 176 162–225
0.16
0.10b
C = 67 193 168–246
BFABP (64 h) E = 69 181 155–227
0.47
C = 64 188 158–233
Neuroketal (6 h) E = 76 653 461–901
0.14
0.27a
C = 68 589 329–798
Neuroketal (64 h) E = 69 576 280–856
0.61
C = 63 602 287–762
The effect of the intervention at the 6 and 64-h time points in the middle column and the effect on the change over time to the right.
E, experimental group; C, control group; IQR, inter quartile range.
aParametric statistics. bNonparametric statistics.
Figure 2. Intervention effect on the blood biomarkers illustrated as log 
ratio for the change in the concentration of the blood biomarkers from 6 
to 64 h of age. □ = control group, ■ = experimental group.
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as a potential surrogate outcome of randomized clinical trials 
in preterm infants (14). A systematic review aiming to clarify 
the predictive value of EEG as a surrogate outcome for the 
developmental outcome in this group of infants is currently 
being conducted (26). We could not implement continuous 
EEG monitoring in this complex, multicentre SafeBoosC II 
trial and the age of 64 h was chosen as we hypothesized that 
the end of the intervention was the time with the highest 
likelihood of detecting an accumulated effect of a reduction 
of cerebral hypo- or hyperoxia in the experimental group—
should such be found. This approach was chosen by extrapo-
lation from term infants with severe hypoxic–ischemic brain 
injury in whom the EEG effects last some days (27).
We chose burst rate and SEF as the variables for the EEG 
analyses as these are the most commonly used in preterm 
infants and have been related to long-term outcomes (6,7,17). 
Certainly, other more sophisticated analytical methods could 
be used and may be more sensitive to subtle effects of moderate 
cerebral hypoxia (28).
Blood biomarkers. The three blood biomarkers of brain injury 
were explorative outcomes of the SafeBoosC II trial and the 
reduction in the burden of cerebral hypoxia was not reflected 
in any of them.
S100β is the best known of the three brain injury blood bio-
markers and is routinely used in the screening of patients with 
mild to moderate head trauma (29). It is a small calcium-bind-
ing protein present in high concentration in Schwann cells and 
astrocytes (30) and after severe cerebral damage, it leaks from 
the tissue into the systemic circulation.
A small study in preterm infants found that the level of 
S100β in blood is correlated to the degree of intraventricular 
hemorrhage (31), whereas a recent larger study showed no cor-
relation (32). The level of S100β is increased in term asphyxi-
ated infants and the concentrations have been correlated to 
the degree of hypoxic–ischemic encephalopathy (9). Whereas 
hypoxic encephalopathy in term infants typically is the result 
of a terminal, short and severe hypoxia, the preterm infants 
in the SafeBoosC II trial were more likely exposed to various 
grades of cerebral hypoxia for shorter or longer periods during 
the first 72 h of life. There was no difference in S100β between 
the two intervention groups. This could be because the burden 
of cerebral hypoxia—even though the reduction in the experi-
mental group was highly significant—was insufficient for the 
release of the intracellular S100β into the systemic circulation. 
Negative correlations between NIRS levels and S100β in criti-
cally ill children have been shown previously (33).
BFABP is a small molecule (15  kDa), which is rapidly 
excreted by the kidneys without cleavage. It is released from 
astrocytes as response to mechanical damage, ischemia, and 
oxidative brain damage (34). BFABP has not been investigated 
previously in extremely preterm infants, but is known to be 
elevated in patients with various neurodegenerative diseases 
(10). In adult patients with acute ischemic stroke, BFABP is 
elevated from 2 to 3 h after the event and remains increased 
for at least 5 d (34). There was no difference in the level of 
BFABP between the two intervention groups in the SafeBoosC 
II trial, which again could be explained by the insufficiency 
of a moderate global cerebral hypoxic exposure—compared to 
stroke patients experiencing an acute and severe local cerebral 
hypoxia.
Neuroketal concentrations in cerebrospinal fluid have been 
reported to be increased in preterm infants with cerebral 
white matter damage on magnetic resonance imaging (11). 
Neuroketals are compounds produced by free radical-induced 
peroxidation of docosahexenoic acid, which is solely present in 
the brain and especially vulnerable to oxidative stress (35). As 
the burden of hyperoxia was unaffected by the intervention in 
the SafeBoosC II trial, it may not be surprising that the neuro-
ketal was the same in the two groups.
We did not observe any significant effects of cerebral oxy-
genation monitoring on blood levels of S100β, BFABP, or neu-
roketal. Our present analyses are not able to decide if these 
blood biomarkers are predictive of long-term cerebral out-
come in this population. Accordingly, we do not yet know if 
these blood biomarkers are valid surrogate outcomes for cere-
bral damage in relation to NIRS (14–16).
Limitations of the Trial
We did not measure the PCO2  in the SafeBoosC II infants, but 
all other physiological variables were comparable in the two 
intervention groups (fractional inspired oxygen, peripheral 
capillary oxygen saturation, mean airway pressure, heart rate, 
and arterial blood pressure) (13). The incidence of seizures in 
this population is high, however, the burden of the seizure is 
low; exceeding 90 s during 24 h of recording on day 3 in only 
3% of the infants and thus only amounts to less than 0.2% of 
recording time (36). In this study, we did not investigate the 
seizure activity. The blood biomarker and EEG outcomes are 
unvalidated short-term surrogate outcomes of the interven-
tion and assessment of neurodevelopmental outcome at 2 y of 
age in this cohort is ongoing. This may enable the validation of 
these surrogates (14–16).
Our results do not support the hypothesis that the 
SafeBoosC II NIRS intervention would be effective in reduc-
ing brain injury. First, the chosen surrogate outcomes may not 
be valid. EEG and the blood biomarkers are not established 
markers for brain injury in preterm infants. However, we 
examined them as prime candidates and therefore consider 
the absence of any difference between the groups as an impor-
tant signal. Is it possible that the reduced burden of cerebral 
hypoxia was irrelevant for the brain? Although the “burden 
of cerebral hypoxia”—the accumulated area under the curve 
expressed in %hours—amounted to more than 200 %hours in 
some infants, the threshold used as the alarm limit for inter-
vention and for the calculation of the burden was 55% (13). 
In piglet experiments at term, cerebral oxygenation has to be 
kept below 30% before severe abnormalities occur in the EEG 
(37,38) and below 35% for several hours to induce brain injury 
(39). Furthermore, preterm infants are normally exposed to 
arterial oxygen saturation of 70% or less in utero, and some 
neonatal units in the past (1990s) targeted arterial saturation 
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at low ranges and thereby reduced the risk of retinopathy of 
prematurity, without increasing the risk of cerebral palsy (40), 
though it has later been shown that low levels of arterial satu-
ration increase mortality (41). Therefore, our results raise the 
possibility that cerebral hypoxia at the levels that are common 
in extremely preterm infants during the first days after birth is 
really not significant as an etiology for brain (tissue) injury as 
detectable by EEG and the selected molecular biomarkers at 
64 h of age.
Conclusions
Whereas cerebral hypoxia was reduced to less than half in the 
experimental group, the result was neither reflected in the 
EEG, nor in the three assessed blood biomarkers.
METHODS
Study Design and Patient Characteristics
The SafeBoosC II randomized clinical trial is a multicentre, blinded, 
feasibility medical device trial (42). One hundred and sixty-six 
extremely preterm infants from eight European countries each repre-
sented by one NICU were included (1 June 2012–31 December 2013) 
(13). The infants were randomized to the experimental group (cere-
bral NIRS monitoring with visible cerebral oxygenation levels com-
bined with an evidence-based treatment guideline (12) listing possible 
interventions if the cerebral oxygenation was out of range: 55–85%) 
vs. control group (blinded collection of cerebral oxygenation levels 
combined with treatment as usual). In both intervention groups, the 
NIRS monitoring was started within 3 h after birth and ended at 72 h 
of life. The trial is registered at ClinicalTrial.gov, NCT01590316; the 
protocol is available in full at http://www.safeboosc.eu.
The EEG Recording
Recording was specified in a standard operating procedure. At post-
natal age of 64  h (±8) at least 120  min of good quality EEG with 
amplitude-integrated EEG tracing was recorded. Electrodes were 
placed at P3 and P4 positions according to the international 10–20 
system. Needle, disc, or hydrogel electrodes could be used according 
to local practice and additional electrodes were allowed. The electrode 
impedance was less than 20 kΩ during the recording. If the child was 
treated with morphine, other opioids, or sedative medications this 
was noted in an electronic record form. The raw EEG data were ano-
nymized and uploaded for central analysis via a file transfer protocol.
EEG Analysis
All EEG analysis was performed in Matlab version R2014b 
(MathWorks, Natick, MA).
Artifact rejection. The raw EEG was band pass filtered (0.5–30 Hz) 
using a zero-phase filter. Since the amplitude-integrated EEG trace 
was missing in some infants, the filtered EEG data were converted 
into range EEG (rEEG) (43) to enable a standardized artifact rejec-
tion. The rEEGs were split in 10-min epochs for visual inspection. 
Artifacts in the rEEG epochs were independently visually identified 
by two of the authors (GG and AMP) blinded to treatment allocation 
and the clinical history of the infant. Kappa statistics was used to cal-
culate the level of agreement. For epochs with disagreements, the raw 
EEG was reviewed and the epoch rejected if the presence of artifacts 
was confirmed.
Classification of rEEG. The rEEGs were visually classified into four 
categories: (i) severe burst suppression; (ii) burst suppression (mainly 
flat lower margin); (iii) discontinuous (lower margin below 25  μV 
most of the time); or (iiii) continuous (lower margin above 25 μV).
IBIs were measured as the time (in seconds) between bursts of 
nested (high-frequency) oscillations within large slow-wave depolar-
izations using an extraction algorithm based on the co-occurrence 
of a slow (0.5–2 Hz) wave and higher (8–22 Hz) frequency oscilla-
tion. Consecutive events that occurred within 0.5  s of one another 
were counted as one and events of duration less than 4/22 of a second 
were discounted (19). IBIs were calculated for each of the artifact-free 
10-min epochs and expressed as the median of all IBIs in all included 
epochs.
Spectral analysis. For each artifact-free 10-min epoch spectral analy-
ses were conducted using Matlab routines (Neurospec 2.0, Neurospec.
org). The EEG data were segmented into epochs of 2 s with an over-
lap of 50% (1s). After Fast Fourier Transformation, the spectrum was 
subdivided into frequency bands: delta (0.5–4 Hz), theta (4.5–8 Hz), 
alpha (8.5–13  Hz), and beta (13.5–30  Hz). The spectral distribu-
tion was calculated as the square root of the power in each band and 
expressed as percentages adding up to 100%. A grand mean of the 
spectral distribution for each infant was calculated as the mean of all 
epochs.
SEF95 for each infant was defined as the frequency between 0.5 and 
30 Hz, below which 95% of the power was present. SEF95 is expressed 
as a mean of all epochs.
Brain Injury Biomarkers in Blood
Blood sampling, plasma storage and analyses were specified in a stan-
dard operating procedure. At the age of 6 h (±1) and 64 h (±1), 1 ml 
of blood was collected. A blood sample was only taken if the infant 
had an indwelling arterial or venous line. The blood was sampled in 
heparin tubes and centrifuged (1200×g for 12 min) before the plasma 
was transferred to a small screw-cap tube. The samples were kept at 
−40 to −20°C for a maximum of 1 wk, thereafter at −80°C (±10°C) 
for prolonged storage. After inclusion of the last patient, the samples 
were sent on dry ice to a central laboratory (HaemoScan, Groningen, 
The Netherlands).
Laboratory Analysis
The blood samples were analyzed for the three different brain injury 
biomarkers. The laboratory technician was unaware of the medical 
history and allocation of the infant. S100β (50μl) was assessed by 
ELISA. Clone 1B2 monoclonal antibody was used as capture antibody 
(Abnova, Taipei, Taiwan) and biotinylated clone 8B10 as detection 
antibody (Hytest, Turku, Finland). Intra-assay variance is 4.6% and 
the lower level of quantification (LLOQ) is 39 pg/ml. BFABP (50 μl) 
was determined by means of ELISA with BFABP polyclonal capture 
antibodies and monoclonal detection antibody (HaemoScan). Intra-
assay variance is 6.4% and the lower level of quantification is 150 pg/
ml. Neuroketal (60 μl) determination was performed by competitive 
enzyme immunoassay based on purified rabbit antibodies against 
KLH complexed neuroketal (Haemoscan). Intra-assay variance is 
10% and the lower level of quantification is 4.1 pg/ml.
Ethics
The SafeBoosC phase II trial was approved by each hospital’s research 
ethics committee (Hopital Femme Mere Enfants, Lyon, France; 
Rigshospitalet, Copenhagen, Denmark; La Paz University Hospital, 
Madrid, Spain; Cork University Maternity Hospital, Cork, Ireland; 
Wilhelmina Children’s Hospital, Utrecht, The Netherlands; Medical 
University of Graz, Graz, Austria; Fondazione IRCCS Ca’ Granda 
Ospedale Maggiore Policlinico, Milan, Italy; and Rosie Hospital, 
Cambridge University Hospitals, United Kingdom), and where 
required (Austria, Denmark, and France) by the competent authority 
responsible for medical devices. Written informed parental consent 
was mandatory before inclusion in the trial.
STATISTICS
Between-Groups Analysis
EEG. The distribution of the IBIs and SEF95 were tested for normal-
ity, if not normal, the data were transformed. For the EEG outcomes, 
a general univariate regression model of each EEG quantity on GA 
(above or below 26 wk) and on each of the indicators of opioid treat-
ment, of treatment with sedative, of EEG filter, of EEG sampling rate, 
and of type of EEG device was conducted to see which of these quan-
tities had a significant (P < 0.05) effect on the EEG outcome. The vari-
ables with significant effect on the EEG outcomes were included in 
multiple regression models, thereafter the estimated mean (SE) was 
calculated and comparisons between the two groups were conducted.
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Molecular biomarkers. If the molecular biomarkers were not nor-
mally distributed, logarithmic transformation was attempted. For 
data with normal distribution before or after transformation a lin-
ear mixed-model analysis using time, intervention (experimental 
or control), and the interaction between time and intervention was 
conducted. An unstructured covariance matrix was used. The analy-
ses were adjusted by GA (above or below 26 wk) and centre. If the 
data did not follow a normal distribution, the Mann–Whitney test 
was used. For all analyses the two-sided P values with a threshold of 
0.05 were used.
Inter Cluster Correlation
The outcomes of EEG (IBI and SEF95) and the biomarker concentra-
tions were tested for ICC to determine the correlation between the 
infants in each pair of twins. A mixed-model analysis was carried 
out for each of the EEG and biomarker outcomes: using birth (twin 
pair) as a random intercept. If ICC was less than 0.15, then all infants 
were included in the analysis for that outcome. If the ICC was higher 
than 0.15, one twin from each cluster was removed at random (using 
a web-based randomization program (RANDOM.ORG, Dublin, 
Ireland)) and the between-groups analyses were conducted on the 
remaining infants.
Other Analyses
The interobserver agreement for the artifact rejection of the rEEGs 
was estimated as proportion and the Kappa value was estimated.
The analyses were conducted using IBM SPSS Statistics for 
Windows version 20.0.0, (IBM SPSS, Armonk, NY) and SAS version 
9.3, (SAS Institute, Cary, NC).
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